Affiliation:
1. From the Vanderbilt University, Nashville, TN; Southwest Oncology Group Statistical Center and University of Washington, Seattle, WA; Karmanos Cancer Institute, Wayne State University, Detroit, and University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and University of Southern California and University of California Los Angeles Immunogenetics Center, Los Angeles, CA.
Abstract
PURPOSE: An association between expression of ≥ two of five HLA class I antigens (HLA-A2, HLA-A28, HLA-B44, HLA-B45, and HLA-C3; collectively called M5) and response to an allogeneic melanoma vaccine (Melacine; Corixa Corporation, Seattle, WA) has been described in stage IV melanoma. This study investigated whether class I antigen expression impacted relapse-free survival (RFS) after adjuvant therapy with this vaccine. PATIENTS AND METHODS: We performed class I (HLA-A, HLA-B, and HLA-C) serotyping on patients enrolled onto Southwest Oncology Group Trial 9035, a randomized, observation-controlled, phase III trial of adjuvant Melacine. All patients had clinically node-negative cutaneous melanoma (1.5 to 4.0 mm). Interactions between treatment and class I antigen expression were tested. Analyses involved all serotyped patients and were adjusted for tumor thickness, method of nodal staging, sex, ulceration, and primary tumor site. RESULTS: HLA typing was performed on 553 (80%) of the 689 enrolled patients (294 vaccinated and 259 observed). Expression of ≥ two M5 antigens was associated with a superior vaccine treatment effect. Among patients who matched ≥ two of the M5, the 97 vaccine-treated patients had improved RFS compared with the 78 observation patients (5-year relapse-free survival, 83% v 59%; P = .0002). The major components of this effect were contributed by HLA-A2 and HLA-C3. Among those who were HLA-A2–positive and/or HLA-C3–positive, the 5-year RFS for vaccinated patients was 77%, compared with 64% for observation (P = .004). There was no impact of HLA-A2 and/or HLA-C3 expression among observation patients. CONCLUSION: This prospective analysis indicates a highly significant benefit of adjuvant therapy with Melacine among patients expressing ≥ two of the M5 class I antigens, validating a prior observation in stage IV disease. HLA-A2 and HLA-C3 contributed most to this effect. Processed melanoma peptides found in Melacine may be presented by HLA-A2 and HLA-C3 and play a role in preventing relapse in vaccinated patients.
Publisher
American Society of Clinical Oncology (ASCO)
Reference38 articles.
1. Mitchell MS, Kan-Mitchell J, Kempf RA, et al: Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48: 5883,1988-5893,
2. A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens
3. Active-specific immunotherapy for melanoma.
4. Harel W, Goedegebuure PS, LeMay LG, et al: Melanoma-specific lysis by cloned CD4+ and CD8+ T cells from actively immunized melanoma patients. Vaccine Res 2: 41,1993-53,
5. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation
Cited by
174 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献